在牛皮关节炎中准IL-23:对Guselkumab的有效性和利用的审查
Alisha Kashyap1, Kevin M Burningham2, Stephen K Tyring2,3
1John P. and Kathrine G. McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Skin therapy letter
|March 12, 2025
概括
一种IL-23抑制剂Guselkumab在治疗牛皮关节炎 (PsA) 方面表现有前途. 本综述总结了它的有效性和安全性,作为PsA患者的新疗法选择.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮关节炎 (PsA) 是一种慢性炎症状况,具有不同的临床表现.
- 它的发病包括遗传,免疫和环境因素,导致免疫系统的激活.
- 最近的进展凸显了互白素-23/T助手17通路在PsA中的关键作用.
研究的目的:
- 审查古塞尔库马布在牛皮关节炎治疗中的疗效和安全性.
- 评估古塞尔库马布作为治疗选择的临床效用.
- 提供关于古塞尔库马布在PsA管理中的当前证据的概述.
主要方法:
- 关于古塞尔库马布在牛皮关节炎中的研究的文献综述.
- 对临床试验数据关于疗效和安全性的分析.
- 综合关于IL-23抑制在PsA中的作用的证据.
主要成果:
- 古塞尔库马布显示出作为治疗PsA的有效治疗的潜力.
- 该药物为现有疗法和生物制剂提供了替代品.
- 证据表明,在PsA患者中,guselkumab的安全性概况有利.
结论:
- 古塞尔库马布代表了PsA治疗选择的重大进步.
- 用guselkumab针对IL-23通路提供了一个有前途的治疗策略.
- 进一步的研究支持古塞尔库马布在治疗PSA的临床效用.
相关概念视频
T Cell Types and Functions
740
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
740
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107


